2025-09-30
2025 Future XDC New Drug Conference
From April 17th to 18th, 2025, the "Future XDC New Drug Conference" was successfully held in Chengdu. At this interdisciplinary gathering, radiopharmaceuticals, as an industrial focus, continued to play a crucial role in promoting multidisciplinary integration, overcoming technical bottlenecks, and achieving collaborative innovation. As a pioneering innovator in the field of radiopharmaceuticals, Quarkmed has established deep collaborations with upstream and downstream enterprises in the radiopharmaceutical industry chain to jointly explore new opportunities for industrial development.
Under the leadership and promotion of Chengdu Medical City, the first Class-A research, development and production enterprise, Tongrui Biotechnology, which is located in the Medical City's Radioactive Pharmaceutical Industry Park, has initiated the establishment of an innovative radioactive pharmaceutical industry alliance. The alliance includes upstream medical isotope suppliers, United Imaging Central Research Institute focusing on innovative radioactive pharmaceutical research and transformation, Perceptive, a global leader in non-clinical and clinical imaging evaluation, Quarkmed, a CRO provider specializing in clinical development of radioactive drugs, HGB Medical Group establishing international innovative diagnostic and therapeutic centers for radioactive drugs, and Grand Pharmaceutical, which excels in innovative RDC in the industry. The alliance aims to promote collaborative innovation among industry chain partners, solve the bottleneck issue of domestic supply of medical isotopes, empower midstream innovative research and development and automated high-quality production, explore downstream clinical applications, jointly promote industry, and create a bright future for the radioactive pharmaceutical industry.
During the conference, the launch meeting and first draft seminar of the "Technical Specifications for Phase I Clinical Trials of Radiopharmaceuticals" group standard, initiated by China Isotope and Radiation Industry Association and led by Quarkmed, were successfully held.
This project has joined forces with multiple top-tier medical institutions in China, including the First Medical Center of Chinese PLA General Hospital, Beijing Cancer Hospital, Fudan University Cancer Hospital in Shanghai, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Sun Yat-sen University Cancer Center in Guangzhou, and Beijing GB Hospital Co., Ltd., who have all participated in the preliminary draft discussion of this project.
The launch of the "Technical Specifications for Phase I Clinical Trials of Radiopharmaceuticals" project will fill the domestic gap in technical specifications for phase I clinical trials of radiopharmaceuticals. It will provide unified operational procedures and quality standards for relevant trials, and promote the standardized and normalized development of clinical research on radiopharmaceuticals in China.
At the RDC Innovative Technology and Supply Chain Forum, industry chain alliances jointly explored innovative pathways for nuclear medicine, from target discovery to clinical implementation.
The Chairman of the Oceania Nuclear Medicine and Biology Alliance, Dr. Huang Gang, delivered the opening address, sharing updates on nuclear medicine research and innovation. Ms. Chao Yanan, Assistant General Manager and Head of Nuclear Medicine Department at Qurakmed, gave a brilliant presentation on radioactive drug registration strategies and key points of clinical trials.
Insights on imaging-empowered drug development were presented by Mr. Zhou Yun, Chief Scientific Officer of United Imaging Healthcare, and Jan Passchier, Head of Perceptive Global Labs. The paradigm innovation in the entire ecosystem of nuclear medicine clinical research, as practiced by Gobio Medical Group, has been inspiring. Mr. Qiao Haitao, General Manager of Tongrui Biotech, provided comprehensive solutions for the CMC, GMP production, and supply chain of innovative radiopharmaceuticals.
In the final roundtable discussion, Mr. Yuan Dawei, General Manager of Quarkmed, joined executives from Tongrui Biotech, Maistop, Perceptive, GE Healthcare, Gobio Medical Group, and United Imaging to discuss the challenges and opportunities facing the entire industry chain.
In addition, Mr. Yang Guotao, Chief Operating Officer of Quarkmed, was invited to deliver a keynote speech at the sub-forum on "New Isotopes, Latest Regulations on Nuclear Medicine, and Clinical Research of Therapeutic Nuclear Drugs."
The "Ruiqi Tongtu, Hechuang Future" exchange dinner co-hosted by Quarkmed and Tongrui Biotech was grandly held.
Industry representatives from upstream and downstream gathered to discuss cooperation opportunities, share industry insights, and envision the future direction of the radiopharmaceutical industry. At the dinner, attendees engaged in in-depth exchanges, enhancing mutual understanding and cooperation intentions, which laid a solid foundation for the future development of the industry alliance.
Address：Ping An Fortune Center, Lize Financial Business District of Beijing
